Four-fold rise is defined as: - a post-vaccination hSBA titer equal to or higher than (>=) 16 for participants with a pre-vaccination hSBA titer <4; - a post-vaccination hSBA titer >= 4 times the LLOQ for participants with a pre vaccination hSBA titer >= limit of detection (LOD) but < LLOQ; and - a post-vaccination hSBA titer >= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer >= LLOQ.

Analysis was performed on Per Protocol Set (PPS), which included participants who received at least 1 dose of the study intervention to which they were randomized and had post-vaccination data available at the specified timepoint minus participants with protocol deviations that led to exclusion from the PPS.

Four-fold rise is defined as: - a post-vaccination hSBA titer equal to or higher than (>=) 16 for participants with a pre-vaccination hSBA titer <4; - a post-vaccination hSBA titer >= 4 times the LLOQ for participants with a pre vaccination hSBA titer >= limit of detection (LOD) but < LLOQ; and - a post-vaccination hSBA titer >= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer >= LLOQ.

Analysis was performed on Per Protocol Set (PPS), which included participants who received at least 1 dose of the study intervention to which they were randomized and had post-vaccination data available at the specified timepoint minus participants with protocol deviations that led to exclusion from the PPS.

Assessed solicited administration site events include injection site pain, erythema, swelling, induration. Any pain = occurrence of the symptom regardless of intensity grade and any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.

Analysis was performed on Solicited Safety Set (SSS),which included participants who received at least 1 dose of the study intervention and had solicited administration data available during the specified period.

Assessed solicited administration site events include injection site pain, erythema, swelling, induration. Any pain = occurrence of the symptom regardless of intensity grade and any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.

Analysis was performed on Solicited Safety Set (SSS), which included participants who received at least 2 dose of the study intervention and had solicited data available during the specified period.

Assessed solicited systemic events include fever [body temperature >= 38.0°C (celsius) /100.4°F (Fahrenheit)], nausea, fatigue, myalgia, arthralgia, headache.

Analysis was performed on Solicited Safety Set (SSS), which included participants who received at least 1 dose of the study intervention and had solicited systemic data available during the specified period.

Assessed solicited systemic events include fever [body temperature >= 38.0°C/100.4°F], nausea, fatigue, myalgia, arthralgia, headache.

Analysis was performed on Solicited Safety Set (SSS),which included participants who received at least 2 dose of the study intervention and had solicited systemic data available during the specified period.

Unsolicited AE-AE not solicited using an eDiary and spontaneously communicated by a participant/participant's parent(s)/Legally acceptable representative(s) who has signed informed consent. SAEs-events that result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect in the offspring of a study participant/results in abnormal pregnancy outcomes. AESIs-predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it. An MAE is defined as an unsolicited AE for which the participant received medical attention such as hospitalization, or an emergency room visit, or visit to/by a health care provider.

Analysis was performed on the Unsolicited Safety Set (USS), which included participants who received at least 1 dose of the study intervention and had unsolicited AEs during the specific period.

Any AE-untoward medical occurrence in a patient/clinical investigation participant, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. Unsolicited AE-AE not solicited using an eDiary and spontaneously communicated by a participant/participant's parent(s)/Legally acceptable representative(s) who has signed informed consent. SAEs-events that result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect in the offspring of a study participant/results in abnormal pregnancy outcomes. AESIs-predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it.

Analysis was performed on the Unsolicited Safety Set (USS), which included participants who received at least 1 dose of the study intervention and had unsolicited AEs during the specific period.

SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were assessed throughout the study period are reported in this outcome measure.

Analysis was performed on the Unsolicited Safety Set (USS), which included participants who received at least 1 dose of the study intervention and had unsolicited AEs during the specific period.

The immune response to MenABCWY vaccine after the first dose and single dose of MenACWY vaccine was evaluated by measuring the percentage of participants with hSBA titers >= LLOQ against each of the serogroups A, C, W and Y.

Analysis was performed on the Full Analysis Set (FAS), which included participants who received at least 1 dose of the study intervention and had post-vaccination immunogenicity data for the specified analysis at the specified time points.

The immune response to MenABCWY vaccine after the second dose was evaluated by measuring the percentage of participants with hSBA titers >= LLOQ against each of the serogroups A, C, W and Y.

Analysis was performed on the Full Analysis Set (FAS), which included participants who received at least 1 dose of the study intervention and had post-vaccination immunogenicity data for the specified analysis at the specified time points.

The immune response to MenABCWY after first dose and single dose of MenACWY vaccine was evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y in terms of GMTs. For each serogroup, the GMTs with their associated 2-sided 95% confidence intervals were calculated.

Analysis was performed on the Full Analysis Set (FAS), which included participants who received at least 1 dose of the study intervention and had post-vaccination immunogenicity data for the specified analysis at the specified time points.

The immune response to MenABCWY after second dose was evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y in terms of GMTs. For each serogroup, the GMTs with their associated 2-sided 95% confidence intervals were calculated.

Analysis was performed on the Full Analysis Set (FAS), which included participants who received at least 1 dose of the study intervention and had post-vaccination immunogenicity data for the specified analysis at the specified time points.

The immune response to MenABCWY vaccine after first and single dose of MenACWY vaccine are evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y, compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.

Analysis was performed on the Full Analysis Set (FAS), which included participants who received at least 1 dose of the study intervention and had post-vaccination immunogenicity data for the specified analysis at the specified time points.

The immune response to MenABCWY vaccine after second dose are evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y, compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.

Analysis was performed on the Full Analysis Set (FAS), which included participants who received at least 1 dose of the study intervention and had post-vaccination immunogenicity data for the specified analysis at the specified time points.

The immune response to MenABCWY vaccine after second dose was evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively).

Analysis was performed on the Full Analysis Set (FAS), which included participants from only ABCWY Group who received at least 1 dose of the MenABCWY vaccine and had post vaccination immunogenicity data for the specified analysis at the specified time points.

The immune response to MenABCWY after second dose is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). compared to baseline (day 1) in terms of 4-fold rise in hSBA titers. For each of the serogroup B indicator strains, the 4-fold rise is defined as: a post-vaccination hSBA titer >=16 for participants with a pre-vaccination hSBA titer <4; . a post-vaccination hSBA titer >= 4 times the LLOQ for participants with a prevaccination hSBA titer >= limit of detection (LOD) but < LLOQ; and, a post-vaccination hSBA titer >= 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer >= LLOQ.

Analysis was performed on the Full Analysis Set (FAS), which included participants from only ABCWY Group who received at least 1 dose of the MenABCWY vaccine and had post vaccination immunogenicity data for the specified analysis at the specified time points.

The immune response to MenABCWY vaccine after the second dose was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively) in terms of GMTs at baseline (Day 1) and 1 month after second MenABCWY vaccination.

Analysis was performed on the Full Analysis Set (FAS), which included participants from only ABCWY Group who received at least 1 dose of the MenABCWY vaccine and had post vaccination immunogenicity data for the specified analysis at the specified time points.

The immune response to MenABCWY vaccine after second dose was evaluated by measuring the human serum bactericidal activity against each of the N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively) compared to baseline (Day 1) and expressed as GMRs. Within group GMRs was calculated as ratio of GMTs in the post-vaccination timepoint to the pre-vaccination timepoint.

Analysis was performed on the Full Analysis Set (FAS), which included participants from only ABCWY Group who received at least 1 dose of the MenABCWY vaccine and had post vaccination immunogenicity data for the specified analysis at the specified time points.